Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer by 諛뺤꽭�샇
© 2015 Korean Breast Cancer Society. All rights reserved. http://ejbc.kr  |  pISSN 1738-6756 
eISSN 2092-9900This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Breast cancer is a heterogeneous disease. Molecular subtyp-
ing based on the hormone receptor (HR) and human epider-
mal growth factor receptor 2 (HER2) statuses is very impor-
tant to determine a treatment strategy for breast cancer. Mo-
lecular-targeted therapy has improved patient survival in the 
adjuvant setting. For patients with HR-positive breast cancer, 
use of tamoxifen for 5 years can reduce the annual recurrence 
rate by approximately half and the breast cancer mortality by 
a third [1]. Aromatase inhibitors, which are commonly used 
for postmenopausal patients with HR-positive disease, im-
prove the disease-free survival in this population [2]. In com-
bination with chemotherapy, adjuvant HER2-targeted therapy 
with either concomitant or sequential trastuzumab signifi-
cantly improves the disease-free survival and overall survival 
of patients with HER2-positive breast cancer [3-5]. However, 
triple-negative breast cancer (TNBC) remains a challenging 
problem for both clinicians and investigators. TNBC, charac-
terized by the absence of the estrogen receptor (ER), the pro-
gesterone receptor (PR), and HER2, represents approximately 
10% to 20% of breast cancer cases [6]. It is associated with 
poor survival even in patients with stage I breast cancer [7]. 
Owing to the absence of targeted therapeutic agents, conven-
tional chemotherapy remains the main treatment for TNBC.
Adjuvant chemotherapy is a well-established and effective 
treatment for the management of breast cancer, even in ER-
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Purpose: This study aimed to evaluate the survival benefit of dif-
ferent adjuvant chemotherapy regimens in patients with T1-2N0 
triple-negative breast cancer. Methods: Of 67,321 patients who 
were registered in the Korean Breast Cancer Society nationwide 
database between January 1999 and December 2008, 4,033 
patients with T1-2N0 triple-negative breast cancer were includ-
ed. The overall survival of patients who did not receive adjuvant 
chemotherapy was compared with those treated with adjuvant 
anthracycline and cyclophosphamide (AC), 5-fluorouracil, 
anthracy cline, and cyclophosphamide (FAC), or cyclophospha-
mide, metho trexate, and 5-fluorouracil (CMF). Results: The me-
dian follow-up was 52.5 months. Chemotherapy was used in 
87.4% of patients; it was used more commonly in patients with 
T2 tumors, those who were younger, had a higher histologic 
grade, and who showed lymphovascular invasion. The 5-year 
cumulative overall survival rate was 95.4%. Younger age, 
breast-conserving surgery, and adjuvant chemotherapy were 
significantly associated with improved overall survival. The 
5-year cumulative overall survival rate of patients who did not 
receive adjuvant chemotherapy and those treated with AC, FAC, 
and CMF were 92.5%, 95.9%, 95.3%, and 95.9%, respectively. 
On multivariate analysis, the administration of any adjuvant che-
motherapy regimen was significantly associated with improved 
overall survival (p=0.038). No significant difference in survival 
benefit was observed among the three different treatment 
groups. Conclusion: A standard adjuvant chemotherapy regimen 
with the least drug-related toxicity might be a reasonable treat-
ment for patients with T1-2N0 triple-negative breast cancer.
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positive cases [8]. Nevertheless, the toxicity and high cost of 
chemotherapy are potential obstacles of use, for both physi-
cians and patients. To avoid overtreatment with chemother-
apy, studies to identify patients who may benefit from adjuvant 
chemotherapy are currently underway. Although there are 
promising results with gene expression profiling, these studies 
have not yet been shown to help select patients with node-
negative TNBC who could be good candidates for adjuvant 
chemotherapy [9]. In addition, there is no universally accept-
ed standard adjuvant chemotherapy regimen for the treat-
ment of TNBC because of a lack of reliable evidence in sup-
port of a particular regimen. The use of platinum-based che-
motherapy, epidermal growth factor receptor targeted-agents, 
and other novel agents in the adjuvant treatment of TNBC are 
still under investigation [10]. Standard adjuvant chemother-
apy regimens such as the classic cyclophosphamide, metho-
trexate, and 5-fluorouracil (CMF), anthracycline-containing, 
and taxane-containing regimens are currently accepted as 
reasonable choices in routine practice for patients with TNBC 
[10]. Nonetheless, controversy still exists about choosing an 
adjuvant chemotherapy regimen with an acceptable level of 
adverse toxicity for a low-risk population such as patients with 
relatively small node-negative tumors.
As there are currently no available evidence-based preferred 
regimens for TNBC, selection of chemotherapy is commonly 
based on pathologic parameters such as the nodal status and 
tumor size. According to most clinical guidelines, all patients 
with node-positive disease and/or tumors > 1 cm should be 
considered for adjuvant chemotherapy regardless of the mo-
lecular subtype [11]. Despite this recommendation, there is 
no universally accepted protocol to aid in the selection of ad-
juvant chemotherapy regimens for patients with node-nega-
tive TNBC.
The purpose of our study was to evaluate the influence of 
different systemic adjuvant chemotherapy regimens on the 
survival of patients with T1-2 node-negative TNBC enrolled 
from the Korean Breast Cancer Society (KBCS) nationwide 
database.
METHODS
Data source
Patients with newly diagnosed invasive ductal or lobular, T1-2 
node-negative TNBC between January 1999 and December 
2008 were identified from the KBCS database. The KBCS 
database has prospectively collected nationwide breast cancer 
data since 1996. It includes information about patient sex; age 
at diagnosis; cancer stage according to the sixth American 
Joint Committee on Cancer classification; type of surgical 
procedure; histologic findings; ER, PR, HER2, and other bio-
logical marker status; adjuvant treatment; and other miscella-
neous data. Patient survival data were provided by the Death 
Figure 1. Study design.
IDC= invasive ductal carcinoma; ILC= invasive lobular carcinoma; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal 
growth factor receptor 2; CMF=cyclophosphamide, methotrexate, and 5-fluorouracil; FAC=5-fluorouracil, anthracycline, and cyclophosphamide; 
AC=anthracycline and cyclophosphamide.
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Certification of the Korean National Statistical Office and the 
Korean Central Cancer Registry of the Ministry of Health and 
Welfare [12]. One hundred fourteen institutes participate in 
this KBCS database project. Detailed information on the 
KBCS database has been provided previously [12,13]. ER and 
PR status was defined as positive or negative according to the 
standard method of each institution. HER2 positivity was de-
fined as a 3+ score on immunohistochemical analysis and/or 
gene amplification observed with fluorescence in situ hybrid-
ization. Each physician prospectively registered information 
regarding the ER, PR, and HER2 status in the KBCS database, 
according to institutional standards. This retrospective study 
was approved by the Institutional Review Board of the Korea 
Cancer Center hospital (K-1305-002-017).
Between January 1999 and December 2008, 51,739 patients 
with newly diagnosed invasive ductal or lobular breast cancers 
were registered in the KBCS database. We excluded patients 
with incomplete information regarding the ER, PR, and 
HER2 statuses; lymph node metastasis; and adjuvant chemo-
therapy regimens. Male patients and patients with other pre-
vious malignancies, lymph node metastasis, or who under-
went treatment with adjuvant chemotherapy regimens other 
than CMF, anthracycline and cyclophosphamide (AC), or 
5-fluorouracil, anthracycline, and cyclophosphamide (FAC) 
were also excluded. A score of 0–1+ on immunohistochemi-
cal analysis or a negative result after fluorescent in situ hybrid-
ization confirmed the TNBC ER-, PR-, and HER2-negative 
statuses. Of these patients, 4,033 patients with TNBC were in-
cluded in this analysis (Figure 1). The last date of follow-up 
for survival was December 31, 2009. The primary endpoint of 
this study was death caused by any reason. As the KBCS data-
base only provides patients’ survival information, analysis of 
disease recurrence could not be performed. 
Statistical analysis
Data analysis was performed with SPSS version 14.0 (SPSS 
Inc., Chicago, USA). The chi-square test was used to assess 
differences in values between the groups. Survival rates were 
estimated by using the Kaplan-Meier method, and compared 
with the log-rank test. Multivariate analyses were performed 
with the linear logistic regression model and the Cox propor-
tional hazards model. Statistical significance was accepted as 
p-values of < 0.05.
RESULTS
Patient characteristics
Among 51,739 patients with newly diagnosed invasive duc-
tal or lobular breast cancer in the KBCS database, the data 
from 18,867 patients were available for this analysis. Of these 
patients, 21.4% (4,033/18,867) were classified as having T1-
2N0 TNBC (Figure 1). The mean age at diagnosis was 48.5 
± 10.8 years (range, 21–91 years). Most of the tumors were T1 
(53.6%) and had a high histological grade (grade 3; 57.0%). 
Lymphovascular invasion was observed in 591 patients 
(14.7%). Breast-conserving surgery (BCS) was performed in 
57.8% of the patients (Table 1).
Application of adjuvant chemotherapy
Overall, 3,781 patients (86.4%) were treated with adjuvant 
chemotherapy. AC was the most commonly administered 
chemotherapy regimen with 1,419 patients (35.2%) receiving 
this treatment. CMF was administered to 1,190 patients 
(29.5%). FAC was used as an adjuvant treatment for 875 pa-
Table 1. Patients characteristics 
Characteristic
No. of patients (%)
(n=4,033)
Age (yr) 
   ≤50 2,436 (60.4)
   >50 1,592 (39.5)
   Unknown 5 (0.1)
T stage
   T1 2,163 (53.6)
   T2 1,870 (46.4)
Histologic grade
   I 198 (4.9)
   II 964 (23.9)
   III 2,300 (57.0)
   Unknown 571 (14.2)
Histology
   IDC 3,992 (99.0)
   ILC 41 (1.0)
LVI
   No 2,641 (65.5)
   Yes 591 (14.7)
   Unknown 801 (19.9)
Operation
   Mastectomy 1,674 (41.5)
   BCS 2,332 (57.8)
   Unknown 27 (0.7)
Radiotherapy
   None 1,640 (40.7)
   Done 2,197 (54.5)
   Unknown 196 (4.9)
Chemotherapy regimen
   None 549 (13.6)
   AC 1,419 (35.2)
   FAC 875 (21.7)
   CMF 1,190 (29.5)
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; LVI = 
lymphovascular invasion; BCS=breast-conserving surgery; AC=anthracyclin 
and cyclophosphamide; FAC=5-fluorouracil, anthracyclin, and cyclophospha-
mide; CMF=cyclophosphamide, methotrexate, and 5-fluorouracil. 
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tients (21.7%) (Table 1). Chemotherapy was administered to 
91.3% (879/963), 88.9% (1,310/1,473), 87.5% (911/1,029), 
78.3% (346/442), and 38.0% (46/121) of patients aged ≤ 40, 
41–50, 51–60, 61–70, and > 71 years, respectively. Adjuvant 
chemotherapy was more frequently used in patients aged ≤ 50 
years, and in patients who had larger tumors (T2), high histol-
ogic grade tumors, tumors showing lymphovascular invasion, 
and who were treated with BCS (Table 2). In a multivariate 
model, values significantly predictive of adjuvant chemother-
apy use included younger age, T2 tumor, high histologic 
grade, lymphovascular invasion, and BCS (Table 2). 
The AC and FAC regimens were more commonly used for 
patients with high-risk characteristics such as younger age, 
larger tumor size, higher histologic grade tumors, and the 
presence of lymphovascular invasion. In contrast, the CMF 
regimen was more frequently used in patients aged > 50 years, 
and in patients with smaller tumors (T1), lower histologic 
grade tumors, and no lymphovascular invasion (Table 3).
Overall survival
After a median follow-up of 52.5 months, there were 150 
deaths, including 11 unrelated deaths, 69 breast cancer-related 
deaths, and 70 deaths due to unknown reasons. Of the 11 un-
related deaths, heart problems were the cause of death in only 
one patient; the patient was 65 years at diagnosis, was not 
Table 2. Factors associated with use of adjuvant chemotherapy
Factor
Adjuvant chemotherapy (n=3,481) 
No. (%)
None (n=549) 
No. (%)
Univariate analysis Multivariate analysis
p-value Exp(B)
95% CI
p-value
Lower Upper
Age (yr) <0.001
   ≤50 2,189 (89.9) 247 (45.0)
   >50 1,292 (81.2) 300 (54.6) 0.556 0.434 1.713 <0.001
   Unknown 2 (0.4)
T stage <0.001
   T1 1,728 (79.9) 435 (20.1)
   T2 1,756 (93.9) 114 (6.1) 3.166 2.371 4.228 <0.001
Histologic grade <0.001
   I 141 (25.9) 57 (28.8)
   II 795 (82.5) 169 (17.5) 1.959 1.317 2.915 0.001
   III 2,125 (92.4) 175 (7.6) 4.428 2.981 6.577 <0.001
   Unknown 423 (74.1) 148 (25.9)
LVI <0.001
   No 2,264 (85.7) 377 (14.3)
   Yes 548 (92.7) 43 (7.3) 1.534 1.057 2.227 0.024
   Unknown 672 (83.9) 129 (16.1)
Operation <0.001
   Mastectomy 1,403 (83.8) 271 (16.2)
   BCS 2,057 (88.2) 275 (11.8) 1.385 1.074 1.787 0.012
   Unknown 24 (88.9) 3 (0.5)
CI=confidence interval; LVI= lymphovascular invasion; BCS=breast-conserving surgery.
Table 3. Clinicopathologic characteristics according to adjuvant che-
motherapy regimens
Characteristic
AC 
(n=1,419) 
No. (%)
FAC 
(n=875) 
No. (%)
CMF 
(n=1,190) 
No. (%)
None 
(n=549) 
No. (%)
p-value
Age (yr) <0.001
   ≤50 915 (64.5) 587 (67.1) 687 (57.7) 247 (45.0)
   >50 501 (35.3) 288 (32.9) 503 (42.3) 300 (54.6)
   Unknown 3 (0.2) 2 (0.4)
T stage <0.001
   T1 707 (49.8) 379 (43.3) 642 (53.9) 435 (79.2)
   T2 712 (50.2) 496 (56.7) 548 (46.1) 114 (20.8)
Histologic grade <0.001
   I 44 (3.1) 13 (1.5) 84 (7.1) 57 (10.4)
   II 372 (26.2) 102 (11.7) 321 (27.0) 169 (30.8)
   III 883 (62.2) 669 (76.5) 573 (48.2) 175 (31.9)
   Unknown 120 (8.5) 91 (10.4) 212 (17.8) 148 (27.0)
LVI <0.001
   No 1,085 (76.5) 434 (49.6) 745 (62.6) 377 (68.7)
   Yes 172 (12.1) 235 (26.9) 141 (11.8) 43 (7.8)
   Unknown 162 (11.4) 206 (23.5) 304 (25.5) 129 (23.5)
Operation <0.001
   Mastectomy 544 (38.3) 251 (28.7) 608 (51.1) 271 (49.4)
   BCS 870 (61.3) 616 (70.4) 571 (48.0) 275 (50.1)
   Unknown 5 (0.4) 8 (0.9) 11 (0.9) 3 (0.5)
AC=anthracyclin and cyclophosphamide; FAC=5-fluorouracil, anthracyclin, 
and cyclophosphamide; CMF=cyclophosphamide, methotrexate, and 5-fluo-
rouracil; LVI= lymphovascular invasion; BCS=breast-conserving surgery.
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treated with adjuvant chemotherapy, and died 6 years after the 
operation. The 5-year overall survival rate was 95.4% (Figure 
2). Age > 50 years, mastectomy, and no adjuvant chemother-
apy were associated with a significantly increased risk of death 
on univariate analysis (Table 4). Compared to the T1 stage, T2 
showed a greater risk of death but this result did not reach sta-
tistical significance (p= 0.058).
Compared to no adjuvant chemotherapy, adjuvant chemo-
therapy with any regimen had a beneficial effect on overall 
survival (Table 4). The beneficial effect of adjuvant chemo-
therapy was retained after adjustment for age, T stage, and 
surgical procedures (Table 5). When compared with patients 
who did not receive adjuvant chemotherapy, the hazard ratio 
of death was 0.524 (95% confidence interval [CI], 0.325–0.846; 
p = 0.008) in the AC group, 0.516 (95% CI, 0.292–0.912; 
p= 0.023) in the FAC group, and 0.567 (95% CI, 0.357–0.900, 
Figure 2. Overall survival of all patients.
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Table 4. Univariate analysis of overall survival in all patients
Factor
No. 
of patients
Death
5-Year 
OS rate (%)
p-value
Age (yr) 0.009
   ≤50 2,436 77 95.9
   >50 1,592 73 94.6
T stage 0.058
   T1 2,163 63 96.1
   T2 1,870 87 94.6
Histologic grade
   I 198 5 97.0 -
   II 964 41 95.0 0.287
   III 2,300 89 95.0 0.332
LVI 0.254
   No 2,641 82 95.9
   Yes 591 24 95.2
Operation 0.012
   Mastectomy 1,674 85 94.4
   BCS 2,332 63 96.3
Chemotherapy regimen
   None 549 31 92.5 -
   AC 1,419 45 95.9 0.013
   FAC 875 23 95.3 0.034
   CMF 1,190 51 95.9 0.039
OS=overall survival; LVI= lymphovascular invasion; BCS=breast-conserving 
surgery; AC=anthracyclin-cyclophosphamide; FAC=5-fluorouracil-anthracy-
clin-cyclophosphamide; CMF=cyclophosphamide-methotrexate-5-fluorouracil.
Table 5. Multivariate analysis of overall survival in all patients 
Factor Hazard ratio 95% CI p-value
Age (yr) 0.065
   ≤50 1
   >50 1.366 0.981–1.903
T stage 0.003
   T1 1
   T2 1.702 1.205–2.406
Operation 0.110
   Mastectomy 1
   BCS 0.758 0.540–1.065
Chemotherapy regimen 0.038
   None 1
   AC 0.524 0.325–0.846 0.008
   FAC 0.516 0.292–0.912 0.023
   CMF 0.567 0.357–0.900 0.016
CI=confidence interval; BCS=breast-conserving surgery; AC=anthracyclin 
and cyclophosphamide; FAC=5-fluorouraci, anthracyclin, and cyclophospha-
mide; CMF=cyclophosphamide, methotrexate, and 5-fluorouracil. 
Table 6. Univariate analysis of overall survival in patients treated by ad-
juvant chemotherapy
Factor
No. 
of patients
Death
5-Year 
OS rate (%)
p-value
Age (yr) 0.379
   ≤50 2,189 72 95.8
   >50 1,292 47 95.8
T stage 0.022
   T1 1,728 46 96.5
   T2 1,756 73 95.1
Histologic grade
   I 141 5 96.2 -
   II 795 31 95.7 0.756
   III 2,125 72 95.7 0.898
LVI 0.302
   No 2,264 68 96.1
   Yes 548 21 95.3
Operation 0.071
   Mastectomy 1,403 62 95.1
   BCS 2,081 57 96.4
Chemotherapy regimen
   AC 1,419 45 95.9 -
   FAC 875 23 95.3 0.907
   CMF 1,190 51 95.9 0.589
OS=overall survival; LVI= lymphovascular invasion; BCS=breast-conserving 
surgery; AC=anthracyclin-cyclophosphamide; FAC=5-fluorouracil-anthracy-
clin-cyclophosphamide; CMF=cyclophosphamide-methotrexate-5-fluorouracil.
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p= 0.016) in the CMF group. 
There was no significant difference in patient survival rates 
between the chemotherapy regimens employed (AC vs. FAC, 
p = 0.907; AC vs. CMF, p = 0.589; FAC vs. CMF, p = 0.654) 
(Table 6, Figure 3). The multivariate analysis of overall surviv-
al in patients treated with adjuvant chemotherapy showed no 
difference in the survival benefit between the adjuvant che-
motherapy regimens (Table 7).
DISCUSSION
In our study, adjuvant chemotherapy was administered to 
86.4% of patients with T1-2N0 TNBC in South Korea, and it 
significantly improved the overall survival in this retrospec-
tive cohort. No difference in patient survival was observed be-
tween the various adjuvant chemotherapy regimens used. An 
advantage of this study is that it only included patients with 
node-negative TNBC from a large nationwide cohort. There 
are only a few studies examining adjuvant chemotherapy for 
node-negative breast cancer because this group has a better 
prognosis. In addition, most of these studies have focused on 
patients with ER-negative breast cancer, resulting in study co-
horts with a mixture of ER–/HER2+ and TNBC patients. In 
this era of HER2-targeted therapy, the inclusion of a HER2 
overexpression group in this analysis could cause confusion 
about the effects of chemotherapy on survival. 
According to our analysis, the use of adjuvant chemother-
apy was associated with an improved overall survival rate, 
which is in agreement with a previous large retrospective 
analysis [14]. The International Breast Cancer Study Group 
conducted a retrospective study to evaluate the efficacy of 
CMF for each molecular subtype in patients with node nega-
tive disease enrolled in two randomized clinical trials [14]. A 
significant reduction in the hazard ratio for chemotherapy 
versus no chemotherapy was observed for the TNBC subtype 
(hazard ratio, 0.46; 95% CI, 0.29–0.73) [14]. 
The efficacy of CMF, AC, and FAC was similar in our study. 
This result corresponds with the findings of the National Sur-
gical Adjuvant Breast and Bowel Project (NSABP) B-23, 
which was designed to determine whether AC was compara-
ble or superior to CMF when used to treat patients with node-
negative ER-negative breast cancer. They demonstrated no 
statistically significant differences in the outcomes of AC-
treated patients and CMF-treated patients during 8 years of 
follow-up [15,16]. A retrospective study analyzed the respon-
siveness of different breast cancer subtypes to specific chemo-
therapy regimens in the MA5 adjuvant trial [17]. There were 
no significant differences in the disease-free survival (hazard 
ratio, 1.1; 95% CI, 0.6–2.1) and overall survival (hazard ratio, 
1.3; 95% CI, 0.7–2.5) between cyclophosphamide-epirubicin-
5-fluorouracil and CMF in basal-like tumors. Together with 
the findings of our study, these results suggest that any of 
these regimens (CMF, AC, or FAC) is a reasonable therapeutic 
choice in terms of efficacy.
When there is no difference in the efficacy between differ-
ent treatments, drug-related toxicities should be considered 
when selecting the optimal treatment regimen. The classic 
CMF regimen has been a standard treatment for a long time, 
and the safety of this regimen is well known [18,19]. Compar-
isons of drug compliance and toxicity between doxorubicin-
cyclophosphamide and CMF were performed in the NSABP 
B-23 study. The toxicity of four courses of AC therapy was 
similar to that of classic CMF [16]. In contrast, FAC treatment 
significantly induced more episodes of emesis, mucositis, alo-
Table 7. Multivariate analysis of overall survival in patients treated by 
adjuvant chemotherapy
Factor Hazard ratio 95% CI p-value
T stage
   T1 1
   T2 1.155 1.098–2.238 0.021
Chemotherapy regimen
   AC 1
   FAC 0.942 0.570–1.558 0.816
   CMF 1.129 0.754–1.690 0.556
CI=confidence interval; AC=anthracyclin and cyclophosphamide; FAC=5-
fluorouracil, anthracyclin, and cyclophosphamide; CMF=cyclophosphamide, 
methotrexate, and 5-fluorouracil.
Figure 3. Overall survival according to the chemotherapy regimen used. 
The receiving adjuvant chemotherapy showed beneficial effect on over-
all survival compared with not receiving adjuvant chemotherapy. There 
was no significant difference in the survival rates between the chemo-
therapy regimens employed.
CMF=cyclophosphamide, methotrexate, and 5-fluorouracil; FAC=5-
fluorouracil, anthracycline, and cyclophosphamide; AC=anthracycline 
and cyclophosphamide.
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pecia, and cardiotoxicity compared with CMF [20,21]. Ex-
tending the AC chemotherapy regimen from four to six cycles 
increased toxicity, including cardiotoxicity, without survival 
improvement [22]. As the results of our study showed that the 
efficacy of FAC was not different from either that of AC or 
CMF, these latter treatments with less adverse toxicity may be 
considered a better choice for the low-risk group of patients in 
our study, and particularly for older patients. 
Cardiotoxicity is an important issue when studies of adju-
vant anthracycline-containing chemotherapy are conducted. 
Anthracycline-induced cardiotoxicity could not be assessed in 
our study because 46.7% of deaths were caused by unknown 
reasons. Only one death was known to result from a heart-re-
lated problem. 
Although many drugs such as platinum-based drugs, tax-
anes, bevacizumab, epidermal growth factor receptor-targeted 
agents, and poly adenosine diphosphate ribose polymerase 
inhibitors are being investigated as potential therapeutic 
agents for TNBC, there is no generally accepted adjuvant regi-
men for TNBC [10]. Most clinical trials to test these novel 
agents are conducted in high-risk patients; therefore, it would 
take a long time to consider the results and adapt these drugs 
to adjuvant regimens that could be used in routine clinical 
practice for low-risk patients. Until then, physicians and pa-
tients have to choose one of the conventional chemotherapies.
This study has some limitations. Firstly, regimens using tax-
anes were excluded from the analysis. In Korea, the use of tax-
anes in the adjuvant setting for node-negative breast cancer is 
not supported by the National Health Insurance Service. Only 
78 patients with T1-2 node-negative TNBC received adjuvant 
treatment with AC followed by taxane or anthracycline-tax-
ane. There are limited data on the adjuvant use of taxanes in 
patients with node-negative breast cancer, which remains 
controversial [22-25]. Therefore, we excluded these patients as 
well as a small number treated with different regimens con-
taining agents less frequently used in this population, such as 
oral 5-fluorouracil, vinorelbine, capecitabine, and gem-
citabine. Secondly, TNBC was classified by data that was col-
lected at each institute since 1999. The KBCS database recom-
mends the results of ER, PR, or HER2 examinations should 
be classified according to each institute’s guideline and has no 
specific pathological validation program. Therefore, we as-
sume that part of data would not match with the American 
Society of Clinical Oncology/College of American Pathol-
ogists guideline for HER2, which was written in 2007. In add-
ition, the exact dose, cycles, and routes of administration of 
adjuvant chemotherapy were not provided by the KBCS data-
base. We analyzed the survival data based on only the chemo-
therapy regimen. Lastly, patients with T1a/b tumors were in-
cluded in the analysis, and the merit of adjuvant chemother-
apy in these patients is debatable. Administration of adjuvant 
chemotherapy was not associated with a significantly higher 
recurrence rate in T1a/bN0 HER2-positive breast cancer or 
TNBC [26-28]. We incorporated this group of patients be-
cause the KBCS database has only limited data on T stage 
subclassifications, even though the inclusion of this popula-
tion might dilute the results of the analysis.
In conclusion, currently used standard adjuvant chemo-
therapy regimens improved the overall survival in patients 
with T1/2 node-negative TNBC. There was no significant dif-
ference in the survival of patients administered CMF, AC, or 
FAC regimens. In the future, randomized prospective studies 
should lead to the development of new adjuvant treatment 
modalities for low-risk patients with TNBC. Currently, the se-
lection of standard chemotherapy regimens with fewer drug-
related adverse toxicities may be the most reasonable choice.
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